Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 434,478 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. The trade was a 27.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $10.83 on Tuesday. The stock’s 50 day simple moving average is $10.79 and its 200-day simple moving average is $11.45. The stock has a market cap of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 1-year low of $9.93 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at approximately $39,000. GAMMA Investing LLC lifted its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after acquiring an additional 1,507 shares during the period. Finally, Quarry LP increased its stake in Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.